Excessive Dopamine Neuron Loss in Progressive Supranuclear Palsy

Mov Disord. 2008 Mar 15;23(4):607-10. doi: 10.1002/mds.21907.

Abstract

Progressive supranuclear palsy (PSP) and Parkinson's disease (PD) differ in their response to dopaminergic replacement therapies, despite having a similar degree of neuronal degeneration in the dopaminergic substantia nigra. We observed more widespread dopamine neuron loss in the extranigral A10 midbrain cell groups in PSP compared with PD. These cell groups innervate subcortical and cortical regions and may be required for adequate response to levodopa therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Disease Progression
  • Dopamine / deficiency*
  • Dopamine / metabolism
  • Dopamine Agonists / therapeutic use
  • Female
  • Humans
  • Levodopa / therapeutic use
  • Male
  • Nerve Degeneration / metabolism*
  • Neurons / metabolism*
  • Neurons / pathology*
  • Substantia Nigra / metabolism*
  • Substantia Nigra / pathology*
  • Supranuclear Palsy, Progressive / drug therapy
  • Supranuclear Palsy, Progressive / metabolism*
  • Supranuclear Palsy, Progressive / pathology*

Substances

  • Dopamine Agonists
  • Levodopa
  • Dopamine